No products in the cart.

Hero MCM-10 Reishi vs ashwagandha
Home/ Compare/ Reishi vs Ashwagandha

Reishi vs Ashwagandha: A Fungus, a Root, Two Liver Signals

Ganoderma lucidum is a bracket fungus graded on beta-glucans and ganoderic acid triterpenoids. Withania somnifera is a nightshade whose root is graded on withanolides. They share a shelf and a marketing vocabulary, and no analytical method at all.

Both have published liver case reports. Ashwagandha’s run to 25 collected patients including three deaths and have prompted a Danish prohibition. Reishi’s are isolated and attached to powdered preparations.

Third Party Tested Batch Certificates Of Analysis Highest Quality Full Spectrum Global Shipping 100% Organic
Third Party Tested Batch Certificates Of Analysis Highest Quality Full Spectrum Global Shipping 100% Organic

At a glance

Property
Reishi
Ashwagandha
Species
Ganoderma lucidum, a bracket fungus.
Withania somnifera, a cultivated nightshade.
Part used
Fruiting body, lacquered and too hard to eat.
Root, dried and powdered or extracted.
Key measured compounds
Beta-glucans together with ganoderic acid triterpenoids.
Withanolides, a group of steroidal lactones.
Beta-glucan content
Inferred by subtraction, and the hydrolysis acid alters it.
No such figure; a root carries no fungal cell wall.
Extraction method needed
Both hot water and alcohol, as the two classes differ in solubility.
Aqueous alcohol, which returned the highest withanolide content.
Traditional use context
Simmered as a decoction in Asia for about 2,000 years.
A root preparation of Ayurvedic origin in India.
Human trials
Five randomised cancer trials and five in 398 adults enrolled, 3 trials with usable data.
Five trials in 254 adults and five more in 400.
What the evidence does not show
Any movement in blood glucose or lipid endpoints.
Agreement between trials; anxiety heterogeneity hit 98%.
Endoca product
Red Reishi Mushroom Extract, 280 mg per serving, organic capsules.
Endoca does not sell ashwagandha in any form.

What these two actually are

A fungus and a flowering plant, brought together only by how they are marketed. Reishi is a hard varnished bracket from a tree trunk, far too tough to eat, so every reishi product sold is a preparation of one kind or another. Ashwagandha is a farmed shrub related to the tomato and to deadly nightshade, and what is traded is its root. There is no marker compound in common, no shared assay and no shared monograph, which means a sentence ranking one above the other is ranking nothing at all.

Reishi’s quality turns on part used and on solvent. Fruiting body against mycelium grown on a grain substrate determines how much of a glucan figure is genuinely fungal, since grain brings starch and starch is an alpha-glucan. And because reishi carries two useful compound classes of opposite solubility, a single-solvent extract is incomplete by construction.

Ashwagandha’s quality turns on withanolide load instead. Nine marketed Withania somnifera formulations assayed by chromatography varied widely in total withanolide content, so two capsules of equal stated weight need not contain comparable material at all.

Beta-glucans, and why the number on the label may not mean what you think

MCM-10 Reishi vs ashwagandhasecond section

Reishi’s beta-glucan percentage is a subtraction and it is unusually method-dependent. Total glucan is released by acid hydrolysis and read as glucose, alpha-glucan from starch and glycogen is measured separately using glucoamylase, and beta-glucan is the gap between them. In the validation study behind that method, Ganoderma lucidum was one of only two species in which sulfuric acid produced significantly higher values than hydrochloric. Two careful laboratories can publish two different reishi percentages from one batch.

Solvent costs reishi half its chemistry if chosen badly. Beta-glucans dissolve in hot water, ganoderic acids require alcohol, so a water-only reishi extract can hold a perfectly honest glucan figure and no triterpenoids whatsoever.

Ashwagandha has no beta-glucan figure because there is no fungal cell wall in a root. Its equivalent measure is withanolide content, and solvent dictates that just as firmly: method development on the root found aqueous alcohol mixtures gave the highest total withanolide content. The conclusion holds on both sides. A percentage quoted without its method and solvent cannot be verified, and a milligram weight describes how much powder sits in the capsule.

What the human evidence shows

Reishi
In five randomised cancer trials, tumour response alongside chemotherapy returned a risk ratio of 1.50 with a confidence interval of 0.90 to 2.51.
At 1.4 to 3 grams daily, HbA1c did not move across 130 participants, weighted mean difference minus 0.10 percent, 95 percent CI minus 1.05 to 0.85, and nor did total cholesterol, LDL cholesterol or body mass index across 107.
No reishi trial has reported long-term survival, and the cancer trial quality was judged generally unsatisfactory.
Ashwagandha
Across five randomised trials in 254 adults, Hamilton Anxiety Scale scores fell 5.96 points, with heterogeneity of 98 percent between the trials.
Across five trials in 400 adults, sleep measures moved by a standardised mean difference of 0.59, mostly above 600 mg daily and past 8 weeks.
Quality of life showed no significant change in that review, whose authors noted that data on serious adverse effects remain limited.

Each of these columns shows a different way of being unproven. Reishi’s cleanest endpoints came back flatly null. Ashwagandha’s mostly came back positive, but the component trials contradicted one another so badly that the pooled number means very little indeed.

What people get wrong

01 They are both in the same category, so either will do.
That category is a marketing grouping, not an analytical one. Reishi was tested against tumour response and cardiovascular markers, ashwagandha against anxiety scales and sleep. No study has compared them.
02 Ashwagandha carries no safety concerns.
A review to December 2025 identified 25 published cases of ashwagandha-associated liver injury. Eighty percent recovered, one needed a transplant and three died, each with pre-existing cirrhosis.
03 Reishi lowers blood glucose and cholesterol.
It did not. In type 2 diabetes there was no significant change in HbA1c across 130 participants, or in cholesterol, LDL cholesterol and body mass index across 107.

Choosing between them

Safety settles this ahead of the evidence. Ashwagandha is contraindicated in pregnancy and advised against for under-18s and for anyone with liver disease, a thyroid disorder or a heart condition, which removes it from consideration for a large number of people. Reishi has hepatic case reports of its own, both tied to powdered preparations rather than traditional decoctions, which is an argument for buying where batch testing is published rather than against the species itself. If triterpenoids are the reason for choosing reishi, confirm that a dual extraction was used.

How Endoca tests for this

Only one of the pair is an Endoca product. The Red Reishi Mushroom Extract gives 280 mg per serving in organic capsules, and reishi also features in the Organic Mushroom Immune Complex at 300 mg per serving. Batches go to a third-party laboratory and the certificate of analysis is published through the lab portal, covering identity, heavy metals, pesticide residues and microbial load. No ashwagandha is stocked. Endoca has worked from its own farm, own land and own extraction since 2010.

Frequently asked questions

Ashwagandha only. Five trials in 400 adults produced a standardised mean difference of 0.59 on sleep measures, with no significant change in quality of life. Reishi has no sleep trials. Against that, ashwagandha carries liver case reports and is contraindicated in pregnancy.

In isolated reports, yes. A fatal fulminant hepatitis was described in a patient taking Ganoderma lucidum as a powder, with an earlier case reported alongside it, both patients having taken boiled lingzhi beforehand without trouble. No hepatological toxicity appeared across its randomised trials.

A 2020 national risk assessment found no intake level for the root or its extracts below which consumption would be without risk of harm. Denmark acted on that finding in 2023, and Sweden has not prohibited it, but has required companies to show that their ashwagandha products are safe.

Nothing measurable. Five trials were eligible and three supplied usable data, all in type 2 diabetes at 1.4 to 3 grams daily over 12 to 16 weeks. HbA1c showed no change across 130 participants, and neither did total cholesterol, LDL cholesterol or body mass index across 107.

References

01

Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. 2016;4(4):CD007731.

02

Klupp NL, Chang D, Hawke F, et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev. 2015;2015(2):CD007259.

03

Wanmuang H, Leopairut J, Kositchaiwat C, et al. Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder. J Med Assoc Thai. 2007;90(1):179-181.

04

Bjornsson HK, Bjornsson ES, Avula B, et al. Ashwagandha-induced liver injury: a case series from Iceland and the US Drug-Induced Liver Injury Network. Liver Int. 2020;40(4):825-829.

05

McIntyre D, Nguyen P, Kim Y, et al. Ashwagandha (Withania somnifera)-associated liver injury: a scoping review of clinical characteristics and safety considerations. Cureus. 2026;18(5):e109764.

06

Fatima K, Malik J, Muskan F, et al. Safety and efficacy of Withania somnifera for anxiety and insomnia: systematic review and meta-analysis. Hum Psychopharmacol. 2024;39(6):e2911.

07

Cheah KL, Norhayati MN, Husniati Yaacob L, Abdul Rahman R. Effect of Ashwagandha (Withania somnifera) extract on sleep: a systematic review and meta-analysis. PLoS One. 2021;16(9):e0257843.

08

Kumar S, Singh R, Gajbhiye N, Dhanani T. Extraction optimisation for phenolic- and withanolide-rich fractions from Withania somnifera roots. J AOAC Int. 2018;101(6):1773-1780.

09

McCleary BV, Draga A. Measurement of beta-glucan in mushrooms and mycelial products. J AOAC Int. 2016;99(2):364-373.

10

Bundesinstitut fuer Risikobewertung. Ashwagandha: food supplements with potential health risks. BfR Communication 39/2024, 10 September 2024.

11

Food Standards Agency. Call for evidence on the use of ashwagandha in food supplements, closed 2 September 2024; and Regulation (EC) No 1924/2006 as retained in Great Britain law.

12

DTU National Food Institute, Technical University of Denmark. Risk assessment of ashwagandha (Withania somnifera) in food supplements, 2020; and Danish Veterinary and Food Administration measure prohibiting ashwagandha in food supplements, 2023.

Last reviewed 1 October 2026.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.